Scoping Review: What is the prognostic value in diagnosing Mild Cognitive Impairment in older adults at risk of Alzheimer’s dementia.
DOI:
https://doi.org/10.22024/UniKent/03/ajpp.1311Abstract
Background: Mild cognitive Impairment (MCI) is a clinical syndrome that represents the transitional risk state between changes in one’s cognition to developing Alzheimer’s dementia (AD). However, there are no changes to activities of daily living (ADLs) (Petersen, 2004). Approximately 5-15% of those with MCI progress into developing AD annually, however around half of individuals with MCI remain stable for 5 years and there is also evidence of reversal in some cases. This is due to the syndrome’s heterogeneous nature. Non-AD related causes include neurodegenerative, physical, and psychiatric conditions (Dunne et al., 2020). Therefore, rendering MCI’s prognostic value questionable, regarding identifying those at risk of AD. MCI is currently diagnosed in clinical settings by cognitive deficits seen on neuropsychological testing. However, there are variations in diagnostic criteria implemented in both clinical and research settings (Ward et al., 2013). Making an accurate diagnosis of MCI is the first step to identifying a potential prodromal state for AD. At present, there are new avenues of research to identify more accurate methods of identifying MCI-AD conversion that can complement existing cognitive testing via fluid biomarkers and neuroimaging techniques (Dunne et al., 2020). Ultimately, in the absence of licensed disease-modifying options for AD at the MCI stage (Joe and Ringman, 2019), subjecting an individual to unnecessary investigations and management needs to be justified, when considering the syndrome’s prognostic value.
Methods: This qualitative study is a scoping review of 35 research papers, where thematic analysis was conducted to answer the research aims. Papers were selected based on a specific inclusion/exclusion criterion.
Results: Thematic analysis of the 35 papers selected out of a total of 70, generated two main themes and further subthemes which reflects the scope of the literature: 1) Link between MCI and AD-conversion [subthemes of neuroimaging(N), fluid biomarkers (FB) and cognitive testing (CT)]. 91.7% (22 papers) of the studies agree that is there is a link between MCI and AD conversion. 8.3% (2 papers) did not support this theme. Clinical Outcomes of MCI diagnosis (subthemes of promising clinical utility (PCU) and limited clinical utility (LCU)). 50% of the studies demonstrated PCU regarding an MCI diagnosis whilst 50% showed LCU.
Conclusions: The findings demonstrate that there is a link between MCI and AD. However, MCI should not be viewed as a sole cause of cognitive decline, instead it can be viewed as a heterogenous syndrome. Given the lack of standardised clinical guidelines, MCI’s prognostic value lies in viewing as opportunity for treating modifiable risk factors associated with cognitive decline and patient co-morbidities. Ultimately, the results demonstrate a lack of clinical translation of research findings unless drastic changes occur in funding, standardisation of diagnostic criteria, recruitment of adequate sample sizes and conduction of longitudinal studies. With the advent of disease-modifying treatment for AD on the horizon, this may evoke such changes that are required to increase the prognostic value of MCI as a diagnosis in older adults at risk of AD.
Downloads
Published
How to Cite
Issue
Section
License
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
AJPP requests that, as the creator(s)/author(s) of the manuscript you are submitting, that you assign certain rights to the manuscript to the AJPP in exchange for undertaking to publish the article in electronic form and, in general, to pursue its dissemination throughout the world. The rights the AJPP requests are:
- The right to publish the article in electronic form or in any other form it may choose that is in keeping with its role as a scholarly journal with the goal of disseminating the work as widely as possible;
- The right to be the sole publisher of the article for a period of 12 months;
- The right to make the article available to the public within a period of not more than 24 months, as determined by relevant journal staff of the AJPP;
- The right to grant republication rights to itself or others in print, electronic, or any other form, with any revenues accrued to be shared equally between the author(s) and the journal;
- The right to administer permission to use portions of the article as requested by others, seeking recompense when the AJPP sees it as warranted;
- The right to seek or take advantage of opportunities to have the article included in a database aimed at increasing awareness of it;
- As the author(s), the AJPP wishes you to retain the right to republish the article, with acknowledgement of the AJPP as the original publisher, in whole or in part, in any other pbulication of your own, including any anthology that you might edit with up to three others;
- As the author(s), the AJPP wishes you to retain the right to place the article on your personal Web page or respository of your university or institution. The AJPP askes that you include this notice: A fully edited, peer-reviewed version of this article was first published by the Advanced Journal of Professional Practice, <Year>, <Volume>, <Issue>, <Page Numbers>.
- You retain the right to unrestricted use of your paper for yourself or for your own teaching purposes.
BY AGREEING TO THE FOREGOING, YOU CONFIRM THAT THE MANUSCRIPT YOU ARE SUBMITTING HAS NOT BEEN PUBLISHED ELSEWHERE IN WHOLE OR IN PART, AND THAT NO AGREEMENT TO PUBLISH IS OUTSTANDING.
SHOULD THE ARTICLE CONTAIN MATERIAL WHICH REQUIRES WRITTEN PERMISSION FOR INCLUSION, YOU AGREE THAT IT IS YOUR OBLIGATION IN LAW TO IDENTIFY SUCH MATERIAL TO THE EDITOR OF THE AJPP AND TO OBTAIN SUCH PERMISSION. THE AJPP WILL NOT PAY ANY PERMISSION FEES. SHOULD THE AJPP BE OF THE OPINION THAT SUCH PERMISSION IS NECESSARY, IT WILL REQUIRE YOU TO PURSUE SUCH PERMISSSION PRIOR TO PUBLICATION.
AS AUTHOR(S), YOU WARRANT THAT THE ARTICLE BEING SUBMITTED IS ORIGINAL TO YOU.
Provided the foregoing terms are satisfactory, and that you are in agreement with them, please indicate your acceptance by checking the appropriate box and proceed with your submission.
